Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMJTYP)

• Drug Name: Frexalimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 2	[1]
Sjogren syndrome	4A43.20	Phase 2	[2]
Systemic lupus erythematosus	4A40.0	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DMMJTYP

Molecule-Related Drug Atlas

Drug(s) Targeting CD40L receptor (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[4]
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[5]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[6]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[4]
Dazodalibep	DM7YII9	Kidney transplant rejection	NE84	Phase 2	[7]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[8]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[9]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[10]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[11]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Antagonist	[1]

References

• [1] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04572841) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sj?gren's Syndrome (pSjS). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05039840) Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [7] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [8] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [9] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [10] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Shattuck Labs.
• [12] Clinical pipeline report, company report or official report of Genmab.